Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

Inclusion Criteria: * Histologically confirmed diagnosis of either FL (grade 1-3A) or MZL (any subtype) with review of the diagnostic pathology specimen at one of the participating institutions. Patients with active histologic transformation are excluded. * No prior systemic therapy for FL or MZL. Prior treatment with radiation therapy or short course steroids is allowed. * Meets at least one criterion to begin treatment based on the modified GELF criteria: * Symptomatic adenopathy * Organ function impairment due to disease involvement, including cytopenias due to marrow involvement (WBC \<1.5x109/L; absolute neutrophil count \[ANC\] \<1.0x109/L, Hgb \<10g/dL; or platelets \<100x109/L) * Constitutional symptoms * Maximum diameter of disease \> 7cm * \>3 nodal sites of involvement * Risk of local compressive symptoms * Splenomegaly (craniocaudal diameter \> 16cm on CT imaging) * Clinically significant pleural or peritoneal effusion * Leukemic phase (\>5x109/L circulating malignant cells) * Rapid generalized disease progression * Renal infiltration * Bone lesions * Patients cannot be in need of urgent cytoreductive chemotherapy in the opinion of the treating investigator. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. (Appendix A) * Age ≥18 years. * Adequate hematologic and organ function: * Absolute neutrophil count \> 1.0x109/L unless due to marrow involvement by lymphoma in which case ANC must be \>0.5x109/L * Platelets …